Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis C virus E1E2 + QS-21 + 3D-(6-acyl) PHAD
- Development stage
- Preclinical
- Lead developer
- University of Maryland College Park
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intradermal, Transdermal
01
Overview
hepatitis C virus E1E2 + QS-21 + 3D-(6-acyl) PHAD is a preclinical-stage vaccine candidate being developed by the University of Pittsburgh and the University of Maryland for the prevention of hepatitis C virus (HCV) infection. The vaccine is formulated as a microneedle patch (MNP) containing a novel native-like secreted form of the HCV E1E2 envelope glycoprotein heterodimer (sE1E2) as the immunogen, combined with a well-established combinatorial adjuvant system consisting of the saponin QS-21 and the synthetic monophosphoryl lipid A derivative 3D-(6-acyl) PHAD (phosphorylated hexa-acyl disaccharide). Delivered via skin-migratory dendritic cells, this thermostable formulation is designed to elicit robust, Th1-skewed humoral and cellular polyfunctional T-cell immune responses, including neutralizing antibodies, without systemic or local reactogenicity.
- Other names
- hepatitis C virus E1E2 + QS-21 + 3D-(6-acyl) PHAD microneedle patchsE1E2 + QS-21 + 3D-(6-acyl) PHADsE1E2 + QS-21 + PHADsecreted E1E2 + QS-21 + 3D-(6-acyl) PHADsecreted E1E2 + QS-21 + PHAD
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on hepatitis C virus E1E2 + QS-21 + 3D-(6-acyl) PHAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis C virus E1E2 + QS-21 + 3D-(6-acyl) PHAD.